Share this article
Share this article
CARLSBAD, Calif., Jan. 14, 2021 /PRNewswire/ As scientists continue to identify new strains of the SARS-CoV-2 virus, including the B.1.1.7 UK variant that studies suggest is more transmissible, genetic sequencing is being used to track these strains and new ones that are emerging, as well as to trace transmission patterns within communities. Today, Thermo Fisher Scientific announced an extension of its SARS-CoV-2 GlobalAccess Sequencing Program to provide additional units of the Ion Torrent Genexus System and Ion GeneStudio S5 Series sequencers at a subsidized price to further support global COVID-19 research and surveillance.
Understanding the virus s genetic code and new variants is critical to assist with genetic tracing and transmission interruption efforts. Further research is also needed to determine how new strains affect people who are infected and vaccine effectiveness. Thermo Fisher s next-generation sequencing (NGS) technology
Share this article
Share this article
REDWOOD CITY, Calif., Jan. 14, 2021 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced preliminary unaudited financial results and other information in connection with its participation in investor presentations, meetings and events during the week of the 39
th Annual J.P. Morgan Healthcare Conference. The Company will post its revised corporate presentation in the investor section of its website.
Key Highlights of 2020
DSUVIA® achieved Milestone C approval from the Department of Defense (DoD), a decision that approves DSUVIA for use in all U.S. Army sets, kits and outfits (SKOs). Initial stocking orders have begun for U.S. Army SKOs and are expected to approximate $30 million over the next three years, dependent on troop deployment schedules.
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster
News provided by
Share this article
Share this article
SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomar
/PRNewswire/ The Russian Direct Investment Fund (RDIF, Russia s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against.
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments
Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T.
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the
INCREASE clinical study of Tyvaso
® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the